Nasus Pharma Ltd. (NSRX)
NYSEAMERICAN: NSRX · Real-Time Price · USD
6.80
-0.05 (-0.73%)
Dec 5, 2025, 4:00 PM EST - Market closed
Nasus Pharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | -1.53 | -1.05 | -1.71 |
| Loss (Gain) From Sale of Investments | 0.44 | -0.22 | 0.09 |
| Stock-Based Compensation | 0.01 | 0.04 | 0.02 |
| Other Operating Activities | 0.01 | 0.08 | -0.41 |
| Change in Accounts Payable | -0.01 | -0.12 | 0.15 |
| Change in Other Net Operating Assets | 0.41 | 0.28 | 0.33 |
| Operating Cash Flow | -0.67 | -1.03 | -1.21 |
| Other Investing Activities | - | - | -0.16 |
| Investing Cash Flow | - | - | -0.16 |
| Short-Term Debt Issued | - | 0.06 | 0.5 |
| Total Debt Issued | - | 0.06 | 0.5 |
| Net Debt Issued (Repaid) | - | 0.06 | 0.5 |
| Issuance of Common Stock | 1 | 1 | 0.97 |
| Other Financing Activities | -0.23 | - | -0.23 |
| Financing Cash Flow | 0.77 | 1.06 | 1.24 |
| Foreign Exchange Rate Adjustments | -0 | 0.01 | -0.01 |
| Net Cash Flow | 0.1 | 0.04 | -0.14 |
| Levered Free Cash Flow | -0.26 | -0.54 | - |
| Unlevered Free Cash Flow | -0.24 | -0.51 | - |
| Change in Working Capital | 0.41 | 0.17 | 0.48 |
Source: S&P Capital IQ. Standard template.
Financial Sources.